Frank Rimerman Advisors’s Edwards Lifesciences EW Stock Holding History

Frank Rimerman Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$522K	Buy	6,519 +9	+0.1%	+$742	0.03%	368
2025 Q4	$555K	Buy	6,510 +414	+7%	+$34K	0.04%	355
2025 Q3	$474K	Buy	6,096 +102	+2%	+$7.97K	0.03%	382
2025 Q2	$469K	Sell	5,994 -240	-4%	-$17.9K	0.03%	363
2025 Q1	$452K	Sell	6,234 -532	-8%	-$38.1K	0.04%	333
2024 Q4	$501K	Buy	6,766 +1,392	+26%	+$97.4K	0.04%	310
2024 Q3	$355K	Sell	5,374 -1,421	-21%	-$103K	0.03%	389
2024 Q2	$628K	Buy	6,795 +6,774	+32,257%	+$600K	0.04%	295
2024 Q1	$2.01K	Hold	21	–	–	﹤0.01%	284
2023 Q4	$1.6K	Buy	+21	New	+$1.46K	﹤0.01%	279

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Frank Rimerman Advisors's EW Position: Q1 2026 in Review

Frank Rimerman Advisors increased its Edwards Lifesciences (EW) stake by 0.14% in Q1 2026, buying an estimated $742 and bringing the position to 6,519 shares worth $522K. The position accounts for 0.03% of the portfolio, ranked #368.

Frank Rimerman Advisors first reported a position in EW in Q4 2023 and has held it in 10 quarters since. The position peaked at $628K in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Frank Rimerman Advisors held 6,519 shares of Edwards Lifesciences worth $522K as of Q1 2026.
Frank Rimerman Advisors bought 9 Edwards Lifesciences shares in Q1 2026, an estimated $742.
Edwards Lifesciences made up 0.03% of Frank Rimerman Advisors's portfolio in Q1 2026, its #368 holding.
Frank Rimerman Advisors first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 10 quarters since.
Frank Rimerman Advisors's Edwards Lifesciences position peaked at $628K in Q2 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.